Literature DB >> 21926266

Thromboxane-induced actin polymerization in hypoxic pulmonary artery is independent of Rho.

Jena Fediuk1, Alexey Gutsol, Nora Nolette, Shyamala Dakshinamurti.   

Abstract

Actin polymerization (APM), regulated by Rho GTPases, promotes myocyte force generation. Hypoxia is known to impede postnatal disassembly of the actin cytoskeleton in pulmonary arterial (PA) myocytes. We compared basal and agonist-induced APM in myocytes from PA and descending aorta (Ao), under hypoxic and normoxic conditions. We also examined effects of thromboxane challenge on force generation and cytoskeletal assembly in resistance PA and renal arteries from neonatal swine with persistent pulmonary hypertension (PPHN) induced by 72-h normobaric hypoxia, compared with age-matched controls. Synthetic and contractile phenotype myocytes from neonatal porcine PA or Ao were grown in hypoxia (10% O(2)) or normoxia (21% O(2)) for 7 days, then challenged with 10(-6) M thromboxane mimetic U46619. F/G actin ratio was quantified by laser-scanning cytometry and by cytoskeletal fractionation. Thromboxane receptor (TP) G protein coupling was measured by immunoprecipitation and probing for Gαq, G12, or G13, RhoA activation by Rhotekin-RBD affinity precipitation, and LIM kinase (LIMK) and cofilin phosphorylation by Western blot. Isometric force to serial concentrations of U46619 was measured in muscular pulmonary and renal arteries from PPHN and control swine; APM was quantified in fixed contracted vessels. Contractile PA myocytes exhibit marked Rho-dependent APM in hypoxia, with increased active RhoA and LIMK phosphorylation. Their additional APM response to U46619 challenge is independent of RhoA, reflecting decreased TP association with G12/13 in favor of Gαq. In contrast, hypoxic contractile Ao myocytes polymerize actin modestly and depolymerize to U46619. Both basal APM and the APM response to U46619 are increased in PPHN PA. APM corresponds with increased force generation to U46619 challenge in PPHN PA but not renal arteries.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21926266     DOI: 10.1152/ajplung.00016.2011

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  14 in total

1.  LIMK (LIM Kinase) Inhibition Prevents Vasoconstriction- and Hypertension-Induced Arterial Stiffening and Remodeling.

Authors:  Mariana Morales-Quinones; Francisco I Ramirez-Perez; Christopher A Foote; Thaysa Ghiarone; Larissa Ferreira-Santos; Maria Bloksgaard; Nicole Spencer; Eric T Kimchi; Camila Manrique-Acevedo; Jaume Padilla; Luis A Martinez-Lemus
Journal:  Hypertension       Date:  2020-06-29       Impact factor: 10.190

Review 2.  Emerging concepts in smooth muscle contributions to airway structure and function: implications for health and disease.

Authors:  Y S Prakash
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-10-14       Impact factor: 5.464

Review 3.  Effects of Post-translational Modifications on Membrane Localization and Signaling of Prostanoid GPCR-G Protein Complexes and the Role of Hypoxia.

Authors:  Anurag S Sikarwar; Anjali Y Bhagirath; Shyamala Dakshinamurti
Journal:  J Membr Biol       Date:  2019-09-04       Impact factor: 1.843

4.  Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats.

Authors:  Xing-Zhen Sun; Shu-Yan Li; Xiang-Yang Tian; Qing-Quan Wu
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

5.  Actin polymerization contributes to enhanced pulmonary vasoconstrictor reactivity after chronic hypoxia.

Authors:  Laura Weise-Cross; Michelle A Sands; Joshua R Sheak; Brad R S Broughton; Jessica B Snow; Laura V Gonzalez Bosc; Nikki L Jernigan; Benjimen R Walker; Thomas C Resta
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-01-26       Impact factor: 4.733

6.  Thromboxane receptor hyper-responsiveness in hypoxic pulmonary hypertension requires serine 324.

Authors:  K T Santhosh; A S Sikarwar; M Hinton; P Chelikani; S Dakshinamurti
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

Review 7.  Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation.

Authors:  Jochen Bauer; Anne Ripperger; Stefan Frantz; Süleyman Ergün; Edzard Schwedhelm; Ralf A Benndorf
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

8.  Dextromethorphan mediated bitter taste receptor activation in the pulmonary circuit causes vasoconstriction.

Authors:  Jasbir D Upadhyaya; Nisha Singh; Anurag S Sikarwar; Raja Chakraborty; Sai P Pydi; Rajinder P Bhullar; Shyamala Dakshinamurti; Prashen Chelikani
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

9.  Furegrelate, a thromboxane synthase inhibitor, blunts the development of pulmonary arterial hypertension in neonatal piglets.

Authors:  Dinesh K Hirenallur-S; Neil D Detweiler; Steven T Haworth; Jeaninne T Leming; John B Gordon; Nancy J Rusch
Journal:  Pulm Circ       Date:  2012 Apr-Jun       Impact factor: 3.017

10.  The α and Δ isoforms of CREB1 are required to maintain normal pulmonary vascular resistance.

Authors:  Lili Li; Katherine Howell; Michelle Sands; Mark Banahan; Stephen Frohlich; Simon C Rowan; Roisín Neary; Donal Ryan; Paul McLoughlin
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.